Production and Purification of Titanium-45 for Positron Emission Tomography Imaging
Nuclear medical imaging relies on the detection of radiation that is emitted from the body after a radioactive isotope that has been fused to a disease targeting molecule (aka radiotracer) is administered to the patient. For example, positron emission tomography (PET) scans can be used to image and diagnose disease in the body with extremely high resolution and sensitivity. The radioactive isotope titanium-45 has the ideal properties to be incorporated into a nuclear imaging agent for PET scans. Unfortunately, the technology required to make the isotope and isolate it in a form that is compatible for attachment to disease targeting molecules is underdeveloped and to date no titanium-45 PET imaging agents have been successfully used in the clinic. Our proposal aims to address this gap in knowledge and establish a reliable and automated system to produce titanium-45. Our industry partner, ARTMS, will seek to commercialise this technology making it accessible to nuclear medicine researchers that can develop new radiotracers based on titanium-45.